CORRECTION article

Front. Pharmacol., 15 November 2019

Sec. Pharmacology of Anti-Cancer Drugs

Volume 10 - 2019 | https://doi.org/10.3389/fphar.2019.01358

Corrigendum: SCD1 Confers Temozolomide Resistance to Human Glioma Cells Via the Akt/GSK3β/β-Catenin Signaling Axis

  • 1. Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China

  • 2. School of Pharmaceutical Sciences, Central South University, Changsha, China

  • 3. National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China

  • 4. Department of Pathology, Xiangya Hospital, Central South University, Changsha, China

  • 5. Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China

  • 6. Center for Molecular Medicine, Key Laboratory for Molecular Radiation Oncology of Hunan Province, Xiangya Hospital, Central South University, Changsha, China

In the original article, there was a mistake in Figure 6D as published. The final submission for the SCD1 bands in Figure 6D was inadvertently truncated too short. The corrected Figure 6D appears below.

Figure 6

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Summary

Keywords

glioblastomas, temozolomide, resistance, SCD1, Akt signaling

Citation

Dai S, Yan Y, Xu Z, Zeng S, Qian L, Huo L, Li X, Sun L and Gong Z (2019) Corrigendum: SCD1 Confers Temozolomide Resistance to Human Glioma Cells Via the Akt/GSK3β/β-Catenin Signaling Axis. Front. Pharmacol. 10:1358. doi: 10.3389/fphar.2019.01358

Received

30 September 2019

Accepted

28 October 2019

Published

15 November 2019

Volume

10 - 2019

Edited by

Julie Gavard, Institut National de la Santé et de la Recherche Médicale (INSERM), France

Reviewed by

Julie Gavard, Institut National de la Santé et de la Recherche Médicale (INSERM), France

Updates

Copyright

*Correspondence: Zhicheng Gong,

†These authors have contributed equally to this work

This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics